ClinicalTrials.gg
Sign In

Candidiasis, Vulvovaginal clinical trials

The registry lists 109 studies for Candidiasis, Vulvovaginal across more than 10 countries. 14 are recruiting or about to start. 85 of them are mainly about Candidiasis, Vulvovaginal (how this is decided). Per ClinicalTrials.gov, last updated 2026-10-23.

Get an email when these change. Save the Candidiasis, Vulvovaginal studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed
70
Status unknown
14
Recruiting
11
Active, not recruiting
5
Withdrawn
3
Not yet recruiting
3

Phase

Phase 3
26
Phase 2
24
Phase 1
10
Phase 4
8
Early Phase 1
4

Where

United States
33
China
7
Spain
6
Sweden
5
France
4
Turkey
4

Who runs them

Scynexis, Inc. (8) · Gedea Biotech AB (4) · Peking University Shenzhen Hospital (3) · Bayer (3) · National Institute of Allergy and Infectious Diseases (NIAID) (3) · Mycovia Pharmaceuticals Inc. (3) · Cidara Therapeutics Inc. (2) · Medinova AG (2)

What is being tested here

Drugs under test in Candidiasis, Vulvovaginal studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

DrugOpenPhase 3All
Probiotic101
Ibrexafungerp058
VT-1161035
Fluconazole023
Encochleated Amphotericin B002
TOL-463002
Clotrimazole002
Boric acid011
Natamycin011
Lactulose011

Coming up

2phase 3 studies under way
7studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 7

Who these studies take

Of the 11 Candidiasis, Vulvovaginal studies recruiting now, 4 (36%) set no upper age limit and 7 (64%) stop at 75 or younger. 3 (27%) take children under 18. 11 (100%) are for women only and 0 (0%) for men only; 4 (36%) take healthy volunteers.

Recruiting studies that take each age, of 11
AgeWomenMen
102 (18%)0 (0%)
1810 (91%)0 (0%)
3011 (100%)0 (0%)
4011 (100%)0 (0%)
5010 (91%)0 (0%)
656 (55%)0 (0%)
754 (36%)0 (0%)
854 (36%)0 (0%)

Across all 109 studies, recruiting or not: 55% stop at 75 or younger and 50% at 65; 16% take children; 97% are for women only and 0% for men only; 28% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Candidiasis, Vulvovaginal studies take

Of 15 phase 3 interventional studies under Candidiasis, Vulvovaginal, half reached primary completion within 12 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 312 mo9–25 · 15 studies——
Interventional, no phase11 mo9–34 · 20 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

Studies

Recruiting first, then most recently updated. Showing 50 of 109. Browse all 109 → or search them.